The Community Oncology Alliance (COA) is applauding the Trump administration for its Medicare payment rule updates for physicians and hospitals, saying that the updates demonstrate that HHS and CMS are serious about implementing major reforms to reduce physicians’ unnecessary paperwork and adding competition into the healthcare system.
On behalf of the Community Oncology Alliance (COA), Ted Okon, executive director of COA, has released a statement regarding the Prescription Drug Pricing Reduction Act.
In response to CMS’ announcement outlining the Radiation Oncology Alternative Payment Model, the Community Oncology Alliance (COA) has expressed concerns over the model being mandatory or “required” by the agency.
Community Oncology Alliance's (COA's) executive director Ted Okon has released a statement expressing disappointment over the Trump administration’s decision to abandon a proposed rule to eliminate rebates in Medicare Part D and Medicaid managed care.
The Community Oncology Alliance (COA) is offering praise for the Senate Finance Committee over its pharmacy benefit manager (PBM) hearing, which COA called a reminder that PBMs refuse to acknowledge their role in rising drug costs.
The Community Oncology Alliance (COA) has submitted formal comments to CMS regarding the agency's proposed national coverage determination for chimeric antigen receptor (CAR) T-cell therapy.
The Community Oncology Alliance has released its 2018 Year in Review, offering a comprehensive look at highlights and successes from the year.
The Community Oncology Alliance (COA) applauded President Donald Trump, HHS Secretary Alex Azar, Inspector General Daniel Levinson, and HHS staff for staking a strong stance against rebates and proposing to overal the current system.
The Community Oncology Alliance (COA) has submitted formal comments to CMS regarding the Medicare Program International Pricing Index Model for Medicare Part B Drugs pre-poposed rule
Community Oncology Alliance (COA) responded to CMS' proposal to ease restrictions on how Medicare Part D and Medicare Advantage plans dictate access to 6 protected drug classes, calling the decision a potential nightmare for vulnerable patients with cancer.
The Community Oncology Alliance (COA) responded to CMS' final Physician Fee Schedule Rule by commending the agency for listening and responding to feedback from stakeholders.
Community Oncology Alliance (COA) submitted formal comments to CMS in support of proposed changes to the 340B Drug Discount Program and site-neutral paymnts put forward in the Hospital Outpatient Prospective Payment (HOPPS) rule. However, they also submitted comments warning against proposals to introduce new third-party middlemen to the Part B system.
Community Oncology Alliance (COA) has submitted formal comments to CMS Administrator Seema Verma on the 2019 Medicare Physician Fee Schedule.
The Community Oncology Alliance (COA) announced their support of CMS’ 2019 Outpatient Prospective Payment System (OPPS) Proposed Rule.
Following CMS’ announcement of proposed rules for the 2019 Medicare Physician Fee Schedule, Community Oncology Alliance (COA) released a statement calling the proposals “puzzling.” The statement details concern with 2 proposals.
The Community Oncology Alliance (COA) has voiced its support of the 340B Drug Discount Accountability Act, which would require hospitals to report their total 340B drug purchases and pay a small 0.1% user fee to the Health Resources and Services Administration.
The Community Oncology Alliance (COA) has filed a lawsuit in the US District Court for the District of Columbia, stating that the 2% sequester cut to Medicare Part B drug reimbursement is unconstitutional and illegal, and that it can harm patient care and have a huge impact on the communityc ancer care system.
In a survey released by Community Oncology Alliance (COA), the majority of physicians reported concern over proposals to reform the Medicare Part B program
In response to President Donald Trump's blueprint on lowering drug prices and reducing out-of-pocket costs, Community Oncology Alliance (COA) commended the administration for working to put patients first and lower prices, while also urging caution for unintended consequences.